Advertisement
UK markets close in 11 minutes

  • FTSE 100

    8,269.35
    +64.24 (+0.78%)
     

  • FTSE 250

    20,499.83
    +118.78 (+0.58%)
     

  • AIM

    772.54
    -4.96 (-0.64%)
     

  • GBP/EUR

    1.1830
    -0.0004 (-0.03%)
     

  • GBP/USD

    1.2680
    -0.0042 (-0.33%)
     

  • Bitcoin GBP

    51,221.16
    -61.68 (-0.12%)
     

  • CMC Crypto 200

    1,348.26
    -34.40 (-2.49%)
     

  • S&P 500

    5,494.91
    +7.88 (+0.14%)
     

  • DOW

    38,916.14
    +81.28 (+0.21%)
     

  • CRUDE OIL

    82.31
    +0.74 (+0.91%)
     

  • GOLD FUTURES

    2,378.80
    +31.90 (+1.36%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     

  • DAX

    18,239.51
    +171.60 (+0.95%)
     

  • CAC 40

    7,676.92
    +106.72 (+1.41%)
     
Money:

Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

Apogee Therapeutics to Participate in Upcoming June Investor Conferences

Apogee Therapeutics, LLC
·1-min read
Apogee Therapeutics, LLC
Apogee Therapeutics, LLC

SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that members of management will participate at the following upcoming investor conferences:

Jefferies Global Healthcare Conference
Date: Thursday, June 6, 2024
Time: 8:30 a.m. ET

Goldman Sachs 45th Annual Global Healthcare Conference
Date: Monday, June 10, 2024
Time: 11:20 a.m. ET

A live and archived webcast of the fireside chat and presentation will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

ADVERTISEMENT

About Apogee Therapeutics

Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com.

Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com

Media Contact:
Dan Budwick
1AB
dan@1abmedia.com